$VCNX News

Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

Vaccinex To Report New Clinical Results Of Neoadjuvant Treatment With Pepinemab To Enhance Immunotherapy In Patients With Head And Neck Cancer At ASCO Annual Meeting

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

Vaccinex To Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at AACR in Chicago

Vaccinex plans Nasdaq exit as Alzheimer market pressure grows

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62%

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain

Vaccinex reports new findings from SIGNAL-AD Phase 1b/2 trial of pepinemab

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024

Vaccinex announces it will present new data for Phase 1b/2 SIGNAL-AD study

Vaccinex files for secondary stock offering

Vaccinex files to sell 1.6M shares of common stock for holders

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

Vaccinex exercises warrants for proceeds of $6.2M